Floatz logo

Drospirenone

Abdominal Obesity-Metabolic Syndrome

Rigshospitalet, DenmarkSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
73/ 100

Competitive context

42 Active assets in the Abdominal Obesity-Metabolic Syndrome cohort.

Asset / SponsorPhaseRating
Topiramate
All India Institute of Medical Sciences, Bhubaneswar
Phase 4BBB
ATORVASTATIN
Seoul National University Hospital
Phase 4BBB
Pioglitazone
Philip Kern
Phase 4BBB
OLMESARTAN MEDOXOMIL
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Phase 4BBB
Rosuvastatin
Hamdard University
Phase 4BBB

View all 50 →

Same molecule, other indications

Drospirenone is also rated in:

polycystic ovary syndromeActive
BBB
Indicative · Phase 4
78 / 100
View asset →
obesity disorderActive
CC
Indicative · Phase 1
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →